Redenlab supporting Larimar Therapeutics in Phase 1 SAD Clinical Trial

Redenlab are glad to be supporting Larimar Therapeutics Inc. Phase 1 SAD clinical trial is a double-blind, placebo-controlled, randomized clinical trial to assess the safety of subcutaneously administered CTI-1601 versus placebo in adult subjects with Friedreich Ataxia.

Click here to learn more.

Tags: ,

Related Post

Redenlab announces landmark study in collaboration with Queensland Institute of Medical Research

  • Posted on 11 December, 2024
    MEDIA RELEASE Melbourne - December 2024 – Redenlab, a leader in innovative healthcare solutions, has partnered with the Queensland Institute of Medical...
    Read more

    Expanding the phenotype of Kleefstra syndrome: speech, language and cognition in 103 individuals

    • Posted on 31 March, 2024
      Speech and language impairments are core features of the neurodevelopmental genetic condition Kleefstra syndrome. The speech, language and cognitive profile...
      Read more

      Redenlab’s Chief Science Officer, Adam P. Vogel, PhD, leads groundbreaking study on speech analysis for neurodegenerative diseases

      • Posted on 25 January, 2024
        MEDIA RELEASE Melbourne, 19 January 2024 — Redenlab, a leader in innovative healthcare solutions, ispleased to announce a groundbreaking study...
        Read more